A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, Weide B, Ochsenreither S, Becker J, Bauernfeind FG, Brossart P, Funkner F, Heidenreich R, Kays SK, Muth A, Seibel T, Scheel B, Schoenborn-Kellenberger O, Stosnach C, Daehling A, Strack T, Korolkiewicz R, Gnad-Vogt U (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Journal for ImmunoTherapy of Cancer BioMed Central

Publisher: BMC

City/Town: LONDON

Conference Proceedings Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER

DOI: 10.1136/jitc-2020-sitc2020.0800

Authors with CRIS profile

Lucie Heinzerling Department of Dermatology

Involved external institutions

Universitätsklinikum Münster DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Elbe Kliniken Stade-Buxtehude DE Germany (DE) CureVac GmbH DE Germany (DE) Cogitars GmbH DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Bonn DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg DE Germany (DE)

How to cite

APA:

Eigentler, T., Krauss, J., Schreiber, J., Weishaupt, C., Terheyden, P., Heinzerling, L.,... Gnad-Vogt, U. (2019). A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors. In JOURNAL FOR IMMUNOTHERAPY OF CANCER. LONDON: BMC.

MLA:

Eigentler, Thomas, et al. "A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors." Proceedings of the JOURNAL FOR IMMUNOTHERAPY OF CANCER LONDON: BMC, 2019.

BibTeX: Download